STOCK TITAN
  1. Home
  2. News
  3. ALPMY

Astellas Pharma Inc. - ALPMY STOCK NEWS

Welcome to our dedicated news page for Astellas Pharma (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on Astellas Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astellas Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astellas Pharma's position in the market.

News
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Rhea-AI Summary
IZERVAY demonstrates positive 24-month results in reducing GA growth compared to sham, with consistent safety profile
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
clinical trial
-
News
Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize
Rhea-AI Summary
Astellas Venture Management and MBC BioLabs collaborate on the Astellas Future Innovator Prize, offering entrepreneurial scientists and biotech start-ups one year's access to lab facilities and research capabilities. Last year's winners were Bespoke Therapeutics and Cellinfinity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
News
Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society
Rhea-AI Summary
Astellas Pharma will present new insights into fezolinetant for the treatment of VMS due to menopause at the 2023 Annual Meeting of The Menopause Society. The presentations will include analyses on the efficacy and safety of fezolinetant in patients unsuitable for hormone therapy and the efficacy of fezolinetant on night-time VMS episodes. Real-world data on the prevalence and impact of VMS will also be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry. Ireland
Rhea-AI Summary
Astellas Pharma plans to build a new facility in Ireland at a cost of €330 million to expand capacity and capabilities for aseptic drug products, accelerate development of innovative medicines, and reinforce global supply. The facility will be located in Tralee and will bring specialized roles to the region. The project aims to cut water use by half, reduce operational energy intensity by over one-third, and produce zero waste to landfill. Construction is expected to start in 2024 and be operational by 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
none
-
News
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Rhea-AI Summary
EMA validates Astellas Pharma's Type II variation for XTANDI® (enzalutamide) in the treatment of non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, potentially expanding its use in the EU market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
News
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Rhea-AI Summary
FDA grants Priority Review for XTANDI in prostate cancer, decision expected in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
News
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy
Rhea-AI Summary
Astellas Pharma announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The MAA will be reviewed by the Committee for Medicinal Products for Human Use (CHMP) under the centralized licensing procedure for all 27 member states of the European Union (EU). GA is a form of AMD that can cause irreversible vision loss. The acceptance of the EU MAA does not impact the financial forecasts for the current fiscal year ending March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
News
Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood
Rhea-AI Summary
Astellas Pharma Inc. plans to open a new life sciences facility in Cambridge, Mass. The facility will occupy two floors and house laboratory and office areas. Astellas expects a few hundred Boston-based employees to operate out of the new building. The company aims to enhance innovation and collaboration in the biopharma ecosystem.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
none
-
News
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
Rhea-AI Summary
Astellas Pharma will invest $50 million in Poseida Therapeutics, acquiring approximately 8.8% of the company. Astellas will also have exclusive negotiation rights for licensing Poseida's allogeneic CAR-T cell therapy product candidate for solid tumors. The investment aligns with Astellas' focus on immuno-oncology and its commitment to developing next-generation cancer drugs. Poseida is dedicated to advancing cancer cell therapy and gene therapy using genetic engineering technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.63%
Tags
none
News
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
Rhea-AI Summary
Astellas Pharma Inc. announced that the U.S. FDA approved IZERVAY (TSE: 4503) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. GA impacts an estimated 1.5 million people in the U.S. and can cause irreversible vision loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
Stock ALPMY logo
Astellas Pharma Inc.

OTC:ALPMY

ALPMY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ALPMY Stock Data

16.87B
1.79B
0%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Japan
Chuo Ku